久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Companies

Merck Serono looks to expand value chain

By Liu Jie (China Daily)
Updated: 2011-03-29 13:23
Large Medium Small

BEIJING - The biopharmaceutical company Merck Serono AG says mergers and acquisitions (M&A) will play a part in its development strategy in China, as the company seeks to complete its industry value chain and expand into the grassroots market.

Howard Sui, chairman and president of Merck Serono China Co Ltd, told China Daily on Monday that the company already has a research and development (R&D) center and a trading company in China, and is now seeking businesses engaged in manufacturing and distribution.

"We are selecting information and have had contact with some Chinese companies, but no decision has yet been made," said Sui.

Merck Serono looks to expand value chain

Howard Sui, chairman and president of Merck Serono China Co Ltd

Merck Serono, the prescription medicine division of the global pharmaceuticals and chemicals group Merck KGaA, has annually maintained sales growth of more than 30 percent in China since entering the market in 2007.

Merck Serono set up a trading company in Beijing with an investment of 300 million yuan ($45 million). Its Asian R&D center was established in November 2009, at a cost of 150 million euros ($211 million).

However, the company has no production capability in China, because it lacks the facilities in the market.

"We plan to establish a manufacturing facility in Beijing later this year after a decision was made when the group's senior executives visited China in 2010. The internal approval procedure is expected to be finalized next month," said Sui, without revealing the amount of investment in the new plant, or its production capability.

He also said that M&A activity will combine with organic growth to support the development of the company over the long term.

Merck Serono has introduced 18 drug brands in nine separate fields, treating conditions in the cardiovascular, thyroid, and women's health and fertility fields. The treatments are available at key hospitals in cities nationwide though partnerships with domestic distribution companies.

"If Merck Serono can buy a distributor, it will help the drugmaker to reach the grassroots markets at a relatively low cost," said Li Yu, a researcher at the Samsung Economic Research Institute China.

Related readings:
Merck Serono looks to expand value chain China lures global drug makers
Merck Serono looks to expand value chain Merck begins work on new unit
Merck Serono looks to expand value chain Lilly to continue China expansion
Merck Serono looks to expand value chain Novartis gets stake approval

Merck Serono's parent group has successfully employed an M&A strategy in China. In January, Merck KGaA bought Beijing Skywing Technology Co Ltd, a biopharmaceutical company, for 120 million yuan. In September 2009, it also acquired Suzhou Taizhu Technology Co Ltd, an effect pigment supplier based in Jiangsu province, for 28 million euros to expand its chemical business portfolio.

Merck KGaA has also been active in global M&A. Its latest move is the acquisition of Millipore Corp - a Massachusetts-based biopharmaceutical and life sciences company - in June.

That helped the German group lift its full-year profits and exceed analysts' expectations. The 2010 fiscal year saw post-tax profit climbing 70 percent to 642 million euros.

In 2007, Merck KGaA paid $13.3 billion to acquire Serono, at the time Europe's largest biopharmaceutical company by sales, and establish the Merck Serono joint venture. That deal helped the company to grow its China business by nine or 10 times between 2007 and 2009.

Multinational pharmaceutical companies have recently been conducting an aggressive M&A campaign in China. On March 22, the Swiss drugmaker Novartis AG announced that it had completed the acquisition of an 85 percent stake in Zhejiang-based Tianyuan Bio-Pharmaceutical Co Ltd for 850 million yuan.

France's Sanofi-Aventis SA bought BMP Sunstone Corporation for approximately $521 million in the largest M&A deal in China's pharmaceutical industry.

 

分享按鈕
主站蜘蛛池模板: 亚洲欧美日韩国产vr在线观 | 久草社区视频 | 欧美日韩亚洲一区二区三区在线观看 | 99j久久精品久久久久久 | 一本伊大人香蕉高清在线观看 | 欧美成人欧美激情欧美风情 | 成人五级毛片免费播放 | 免费看又黄又爽又猛的网站 | aaa免费视频| 97在线公开视频 | 自拍视频区 | 亚洲综合久久久久久中文字幕 | 亚洲精品人成网在线播放影院 | 久久观看视频 | 92看片淫黄大片看国产片 | 亚洲天堂成人 | 亚洲视频在线观看免费视频 | 欧美久久视频 | 免费中文字幕在线 | 91精品人成在线观看 | 欧美日韩视频二区三区 | 中文三级视频 | 在线亚洲精品国产波多野结衣 | 国产成人亚洲欧美三区综合 | 成人亚洲国产综合精品91 | 亚洲免费视频在线 | 国产日产久久高清欧美一区 | 国产成人久久精品激情91 | 亚洲欧美视频在线 | 日韩经典在线观看 | 国产成人精品久久一区二区小说 | 精品视频网 | 久久一日本道色综合久久 | 国产精品二区高清在线 | 手机免费看a | 伊人不卡| 三级毛片网| 亚洲一区中文字幕在线 | 亚洲色欧美 | 国产午夜精品理论片在线 | 香蕉视频一级片 |